Evaluation of Endothelial Functions in Essential Hypertensive Subjects in Ekiti State
Main Article Content
Abstract
Background: Endothelial dysfunction plays an important role in vascular complications and pathogenesis of essential hypertension marked by an imbalance between vasodilatory and vasoconstrictive factors, increased inflammatory activation, and pro-atherogenic modifications. This study assessed endothelial functions in essential hypertensive subjects in Ekiti State, Nigeria.
Methodology: A total of 126 participants (63 hypertensives and 63 controls) were recruited. Social demographic information was obtained using a structured questionnaire. Height and weight were measured with a stadiometer and ZT-120 scale, and blood pressure was assessed using a digital sphygmomanometer. ET-1 and P-selectin were quantified using ELISA; nitric oxide and lipid profile using spectrophotometry, with lipid indices calculated. Data were statistically analyzed at p<0.05.
Result: The results revealed that body mass index, family history of hypertension, systolic and diastolic blood pressure, Endothelin-1, Total cholesterol, Triglyceride, Low Density Lipoprotein and P-selectin levels were significantly higher in the essential hypertensive subjects compared to the healthy controls; however, Nitric oxide and High-Density Lipoprotein were significantly lower in the essential hypertensive subjects compared to healthy controls. There was no statistically significant difference in all parameters studied based on age and sex. The results also revealed that Endothelin-1 and P-selectin levels were significantly higher in drug-naive hypertensive subjects compared with those on treatment.
Conclusion: The study highlights the role of endothelial biomarkers in the pathophysiology of essential hypertension, particularly ET-1 and P-selectin, which showed greater sensitivity and specificity statistically may serve as an early indicator of vascular dysfunction and potential targets for risk classification and disease management.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
How to Cite
References
1.Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, Whelton PK. Hypertension. Nat Rev Dis Primers. 2018; 4:18014.
2.Gavrilova A, Bandere D, Rutkovska I, Šmits D, Mauriņa B, Poplavska E, Urtāne I. Knowledge about disease, medication therapy, and related medication adherence levels among patients with hypertension. Medicina. 2019;55(11):715.
3.Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, et al. Endothelial function in cardiovascular medicine: A consensus paper of the ESC working groups on atherosclerosis and vascular biology, aorta & peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis. Cardiovasc Res. 2021;117(1):29–42.
4.Costa D, Benincasa G, Lucchese R, Infante T, Nicoletti GF, Napoli C. Effect of nitric oxide reduction on arterial thrombosis. Scand Cardiovasc J. 2019;53(1):1–8.
5.Chirinos JA, Orlenko A, Zhao L, Basso MD, Cvijic ME, Li Z, et al. Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2020;75(11):1281–95
6.Abraham GR, Williams TL, Maguire JJ, Greasley PJ, Ambery P, Davenport AP. Current and future strategies for targeting the endothelin pathway in cardiovascular disease. Nat Cardiovasc Res. 2023.
7.Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008–24.
8.Tamarit García JJ. Atherogenic indices: Usefulness as predictors of cardiovascular disease. Clin Investig Arterioscler (Engl Ed). 2022;34(5):269-70.
9.Drwiła D, Rostoff P, Nessler J, Konduracka E. Prognostic value of non-traditional lipid parameters: Castelli Risk Index I, Castelli Risk Index II, and triglycerides to high-density lipoprotein cholesterol ratio among patients with non-ST segment elevation myocardial infarction during 1-year follow-up. Kardiologiia. 2022; 62:60–6
10.Dharmaraj S, Rajaragupathy S, Denishya S. A descriptive study of atherogenic indices in patients admitted to a tertiary care hospital. Cureus. 2022;14:e32231.
11.Mahdavi-Roshan M, Shoaibinobarian N, Noormohammadi M, Shokrzadeh M, Amini SM, Bijani A, et al. Inflammatory markers and atherogenic coefficient: early markers of metabolic syndrome. Int J Endocrinol Metab. 2022;20:e127445.
12.Wambui D, Mohamed S, Asiki G. Prevalence of and factors associated with high atherogenic index among adults in Nairobi urban informal settlements: The AWI-gen study. PLOS Glob Public Health. 2022;2:e0000224.
13.Bhardwaj S, Bhattacharjee J, Bhatnagar M, Tyagi S, Delhi N. Atherogenic index of plasma, Castelli risk index and atherogenic coefficient—New parameters in assessing cardiovascular risk. Int J Pharm Biol Sci. 2013;3(3):359-64.
14.Dun X, Xu H, Zhang Y, Chen D, Ye M, Zou Y, et al. Physical activity, obesity, and hypertension among adults in a rapidly urbanised city. Int J Hypertens.
2021;2021:9982562.
15.Nilsson PM. Early vascular aging in hypertension. Front Cardiovasc Med. 2020;7:6.
16.Yu B, Chen X, Lu D, Yan H, Wang P, et al. Trends in prehypertension and hypertension risk factors in US adults: 1999–2012. Front Cardiovasc Med. 2022;9:948561.
17.Oluboyo AO. Evaluation of selected renal markers in hypertensive subjects in Ekiti State, Nigeria. Int J Med Lab Res. 2020;5(2):13–9.
18.Odewusi OO, Olaifa BA, Bamishaye DA, Omon EA, Ogunfolakan OO, Oguntuase MO. Auto-immune cardiac degeneration as a complication of essential hypertension. Int J Pharm Biomed Sci. 2024;4(2):97–104.
19.Omon EA, Oluboyo AO, Odewusi OO. Assessment of inflammatory markers among hypertensive women in a Nigerian population. Indian J Cardiovasc Dis Women. 2025;10:96–103.
20.Shariq OA, McKenzie TJ. Obesity-related hypertension: A review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9(1):80–93.
21.Ali N, Ahmed S, Mahmood S, Trisha DA, Mahmud F. The prevalence and factors associated with obesity and hypertension in university academic staff: A cross-sectional study in Bangladesh. Sci Rep. 2023;13(1):7309–13.
22.Schneider RH, Salerno JW, Brook RD. 2020 International Society of Hypertension global hypertension practice guidelines – lifestyle modification. J Hypertens. 2020;38(11):2340–1.
23.Kostov K, Blazhev A. Circulating levels of endothelin-1 and big endothelin-1 in patients with essential hypertension. Pathophysiology. 2021;28(4):489–95.
24.Mutiara (Putri) MP, Hartopo AB, Inggriani MP, Fachiroh J, Dewi FST. Endothelin-1 level in hypertensive subjects between coronary artery disease and healthy populations. J Hypertens. 2022;40(Suppl 2):e7–e8.
25.Blann AD, Tse W, Maxwell SJ. Increased levels of the soluble adhesion molecule E-1selectin in essential hypertension. J Hypertens. 2019; 12:925–8.
26.Verhaar MC, Beutler JJ, Gaillard CA. Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin. J Hypertens. 2020;16:45–50.
27.Ferri C, Bellini C, Desideri G. A clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion. Hypertension. 2021;32:862–8.
28.Barbadoro P, Ponzio E, Coccia E, Prospero E, Santarelli A, Rappelli GGL, D’Errico MM. Association between hypertension, oral microbiome and salivary nitric oxide: A case-control study. Nitric Oxide. 2021; 106:66–71.
29.Zhang S, Wu S, Zheng V, Hu Z, Zhou F. Oxidative stress and nitric oxide signaling related biomarkers in patients with pulmonary hypertension: a case-control study. BMC Pulm Med. 2020;15(1):1–8.
30.Almashhadani HA. Synthesis of a CoO–ZnO nanocomposite and its study as a corrosion protection coating for stainless steel in saline solution. Int J Corros Scale Inhib. 2021;10(3):1294–306.
31.Ukoh VA, Oforofuo IAO. Plasma lipid profiles in Nigerians with normal blood pressure, hypertension and other acquired cardiac conditions. East Afr Med J. 2007;84(6):264–70.
32.Akpa MR, Agomouh DI, Alasia DD. Lipid profile of healthy adult Nigerians in Port Harcourt, Nigeria. Niger J Med. 2019;15(2):137–40.
33.Harvey JM, Beevers DG. Biochemical investigation of hypertension. Ann Clin Biochem. 2020;27(4):287–96.
34.Oyelola OO, Ajayi AA, Babalola RO, Stein EA. Plasma lipids, lipoproteins, and apolipoproteins in Nigerian diabetes mellitus, essential hypertension, and hypertensive-diabetic patients. J Natl Med Assoc. 1995;87(2):113–8.
35.Albucher JF, Ferrières J, Ruidavets JB, Guiraud-Chaumeil B, Perret BP, Chollet F. Serum lipids in young patients with ischaemic stroke: A case–control study. J Neurol Neurosurg Psychiatry. 2020;69(1):29–33.
36.Miao CY, Ye XF, Zhang W. Association between dyslipidemia and antihypertensive and antidiabetic treatments in a China multicenter study. J Clin Hypertens. 2021;23(7):1399–404.
37.Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol. 2020;11(4):383–8.
38.Dharmaraj S, Rajaragupathy S, Denishya S. A descriptive study of atherogenic indices in patients admitted to a tertiary care hospital. Cureus. 2022;14:e32231.
39.Fernández-Morales JC, de la Peña ML, Alonso-Moraga Á. Protective effect of nitric oxide and its role in DNA repair. Mutat Res Rev Mutat Res. 2018;770:24–36.
40.Chen S, Cheng W. Relationship between lipid profiles and hypertension: A cross-sectional study of 62,957 Chinese adult males. Front Public Health. 2022;10:895499.
41.Pandey S, Kalaria A, Jhaveri KD, Herrmann SM, Kim AS. Management of hypertension in patients with cancer: Challenges and considerations. Clin Kidney J. 2023;16(12):2336–48.